MTFB.L Share News (MTFB)

Motif Bio's Iclaprim Eligible For Incentives With New US Designation

Motif Bio raises £22m via share placing

Biopharmaceutical company Motif Bio has raised £22m via a conditional share placing with institutional investors. The London-listed group said "the placing is conditional on securing shareholder approval and on a successful qualified infection disease product designation being given to its iclaprim

Amphion Innovations Confident After Motif IPO, 2014 Asset Value Fall

Motif Bio Raises GBP22 Million In Discounted Share Placing (ALLISS)

Motif Bio Annual Loss Widened Slightly Ahead Of London IPO

Motif Bio signs deal with leading clinical research organisation

A wholly-owned subsidiary of antibiotic developer Motif Bio has signed letters of intent and interim agreements with a leading global clinical research organisation (CRO). Motif has agreed to invest more than $0.95m under the agreements, which must be paid by the end of July. Under the agreements,

Motif Bio Shares Up As It Moves Towards Iclaprim Clinical Trials

Motif Bio Gets FDA Minutes Confirming Phase III Plans For Iclaprim

Motif Bio Exploring Funding Options For Iclaprim Trials (ALLISS)

LONDON MORNING BRIEFING: Next And Burberry Shares In Fashion

Amphion Shares Up As Motif Bio Gets US FDA Approval For Iclaprim Trial

Motif Bio makes AIM debut, seeks approval for Iclaprim treatment

Clinical stage biopharmaceutical group Motif Bio began trading on AIM on Thursday, after raising £2.8m in its initial public offering. The group, whose 44.09% of issued equity is owned by Amphion, placed shares at 20p each, said it had 64,238,442 ordinary shares in issue and a market capitalisation

BCA Marketplace, Marshall Motor And Motif Bio Begin Trading (ALLIPO)